Adrian R. Krainer
St. Giles Foundation Professorship
Ph.D., Harvard University, 1986
firstname.lastname@example.org | (516) 367-8417
Our DNA carries the instructions to manufacture all the molecules needed by a cell. After each gene is copied from DNA into RNA, the RNA message is "spliced" - an editing process involving precise cutting and pasting. I am interested in how splicing normally works, how it is altered in genetic diseases and cancer, and how we can correct these defects for therapy.
Adrian Krainer’s lab studies the mechanisms of RNA splicing, ways in which they go awry in disease, and the means by which faulty splicing can be corrected. In particular, they study splicing in spinal muscular atrophy (SMA), a neuromuscular disease that is the leading genetic cause of death in infants. In SMA, a gene called SMN2 is spliced incorrectly, making it only partially functional. The Krainer lab found a way to correct this defect using a powerful therapeutic approach. It is possible to stimulate SMN protein production by altering mRNA splicing through the introduction into cells of chemically modified pieces of RNA called antisense oligonucleotides (ASOs). Following extensive work with ASOs in mouse models of SMA, one such molecule, known as nusinersen or Spinraza, was taken to the clinic, and at the end of 2016 it became the first FDA-approved drug to treat SMA, by injection into the fluid surrounding the spinal cord. The Krainer lab is currently using this approach for the study of other diseases caused by splicing defects, including familial dysautonomia. In addition, they are applying antisense technology to stabilize mRNAs that are destroyed by a process called nonsense-mediated mRNA decay (NMD), both to learn about the underlying mechanisms and to develop new therapies. The Krainer lab has also worked to shed light on the role of splicing proteins in cancer. They found that the splicing factor SRSF1 functions as an oncogene, and they characterized the splicing changes it elicits when overexpressed in the context of breast cancer; several of these changes contribute to various aspects of cancer progression. Finally, the lab continues to study fundamental mechanisms of splicing and its regulation, and they identified novel ways in which the U1 snRNA can recognize natural 5’ splice sites that deviate from the consensus.
2019 Life Sciences Breakthrough Prize
2019 Fellow of the National Academy of Inventors
2019 Doctorate Honoris Causa, Tel Aviv University
National Academy of Inventors Fellow, Adrian Krainer
December 11, 2018
Professor Adrian Krainer has been named a National Academy of Inventors (NAI) 2018 Fellow. He is being honored for his work on Spinraza®, the first FDA-approved treatment for spinal muscular atrophy (SMA). NAI Fellows are nominated by their peers; those chosen for the honor demonstrate a highly prolific spirit of innovation in creating or facilitating...
Breakthrough Prize laureates meet at CSHL
December 6, 2018
The joint recipients of the 2019 Breakthrough Prize in Life Sciences, Cold Spring Harbor Laboratory (CSHL) Professor Adrian Krainer and C. Frank Bennett of Ionis Pharmaceuticals, met for the first time since the award ceremony, at the Neurodegenerative Diseases meeting held November 28 through December 1 at CSHL. Recognized by Breakthrough for the development of...
Breakthrough Prize to CSHL professor for SMA research
October 17, 2018
Cold Spring Harbor, NY — Cold Spring Harbor Laboratory (CSHL) Professor Adrian Krainer today received the 2019 Breakthrough Prize in Life Sciences. Collaborators Krainer and C. Frank Bennett from Ionis Pharmaceuticals won for the development of the first effective therapy for the neurodegenerative disease spinal muscular atrophy (SMA), an illness that has been the leading...
Predicting how splicing errors impact disease risk
August 30, 2018
Cold Spring Harbor, NY – No one knows how many times in a day, or even an hour, the trillions of cells in our body need to make proteins. But we do know that it’s going on all the time, on a massive scale. We also know that every time this happens, an editing process...
CSHL helps ring opening bell at Nasdaq
August 21, 2018
On August 17th, the Spinal Muscular Atrophy (SMA) Foundation, along with Cold Spring Harbor Laboratory Professor Adrian Krainer and his research team, rang the opening market bell on the Nasdaq Stock Market. In honor of SMA Awareness Month, the group of advocates, researchers, and clinicians visited the Nasdaq’s New York City headquarters to raise awareness...
Therapeutic RNA corrects splicing defect that causes familial dysautonomia
April 30, 2018
Cold Spring Harbor, NY — Scientists at Cold Spring Harbor Laboratory (CSHL) have identified a therapeutic RNA molecule that corrects the error in genetic processing that leads to familial dysautonomia, a rare inherited neurodegenerative disorder. The experiments, conducted in cells sampled from patients and in a mouse model of the disease, provide proof of the...
New method identifies splicing biomarkers for liver cancer
March 2, 2018
Cold Spring Harbor, NY — Because liver cancer is particularly diverse, genetically, and prone to relapse, identifying biomarkers that can predict disease progression is a critical goal in the fight against it. Researchers at Cold Spring Harbor Laboratory (CSHL), led by CSHL Professor Adrian Krainer, now report in Genome Research that they have developed a...
Welcome to the real world of science, I’ll be your guide
February 5, 2018
LabDish blog Science is not too hard for you to understand. That was Jackie Novatt’s attitude during every tour she gave at CSHL, where she herself was a researcher, and it showed. She wasn’t interested in merely dazzling visitors with high-tech equipment and triumphant success stories. She was determined to show the people on her...
FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL
December 24, 2016
‘A perfect example of why we do basic research,’ says Dr. Bruce Stillman, CSHL president Cold Spring Harbor, NY — Within a week of Christmas day, a drug called nusinersen (Spinraza) will be in the hands of doctors across the nation, who will use it, most urgently, to treat young children with a severe and...
One experiment: A drug for SMA visibly repairs defective cells
December 1, 2016
Think of this pair of images as the scientific equivalent of an exclamation point. Here is proof positive of an idea first advanced in 2003 by CSHL Professor Adrian Krainer and colleagues. In a paper entitled “Correction of disease-associated exon skipping,” they suggested a way to make a drug to treat spinal muscular atrophy. A...
Wong, M. S. and Kinney, J. B. and Krainer, A. R. (2018) Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites. Mol Cell,
Sinha, R. and Kim, Y. J. and Nomakuchi, T. and Sahashi, K. and Hua, Y. and Rigo, F. and Bennett, C. F. and Krainer, A. R. (2018) Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice. Nucleic Acids Res, 46(10) pp. 4833-4844.
Aznarez, Isabel and Nomakuchi, Tomoki T. and Tetenbaum-Novatt, Jaclyn and Rahman, Mohammad Alinoor and Fregoso, Oliver and Rees, Holly and Krainer, Adrian R. (2018) Mechanism of Nonsense-Mediated mRNA Decay Stimulation by Splicing Factor SRSF1. Cell Reports, 23(7) pp. 2186-2198.
Lin, K. T. and Ma, W. K. and Scharner, J. and Liu, Y. R. and Krainer, A. R. (2018) A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma. Genome Res,
Nomakuchi, T. T. and Rigo, F. and Aznarez, I. and Krainer, A. R. (2016) Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay. Nat Biotechnol, 34(2) pp. 164-166.
Anczukow, O. and Akerman, M. and Clery, A. and Wu, J. and Shen, C. and Shirole, N. H. and Raimer, A. and Sun, S. and Jensen, M. A. and Hua, Y. and Allain, F. H. and Krainer, A. R. (2015) SRSF1-Regulated Alternative Splicing in Breast Cancer. Mol Cell, 60(1) pp. 105-17.
Hua, Y. and Liu, Y. H. and Sahashi, K. and Rigo, F. and Bennett, C. F. and Krainer, A. R. (2015) Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev, 29(3) pp. 288-297.Additional materials of the author at
CSHL Institutional Repository